Centrose receives $190K in federal funding to automate drug discovery platform

Madison, Wis. - Centrose, a Madison based bio-pharmaceutical company, has received a $190,000 federal grant to help move its CarboConnect platform toward a completely automated process for sugar-enhanced drug discovery. The funding comes from the National Institute of General Medical Services.

CarboConnect uses automation, targeted sets of sugars, and enhanced biochemistries to more rapidly manufacture and screen new drug leads. Thus far, the platform has led to the discovery of new drugs with the potential to fight problematic diseases.

Centrose's drug improvement technologies have been licensed by the Wisconsin Alumni Research Foundation. The company owns a broad set of patents and patent applications related to how sugars regulate drug activity in the body.

Related stories

• Centrose lands $150K federal grant

• Three technology companies qualify for investor credits

• Centrose receives $160K for anti-cancer program

• Centrose lands $875K, seeks $3 million in total capital